Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044784 | 0.83 | ADORA1 (0.38) | ADORA2AADORA1TMIGD3 | |
| SCHEMBL2306619 | 0.75 | ADORA2A (0.67) | ADORA2AADORA1 | |
| SCHEMBL2307822 | 0.71 | ADORA2A (0.62) | ADORA2AADORA1 | |
| SCHEMBL31045247 | 0.71 | CYP1A2 (0.41) | — | |
| SCHEMBL31044702 | 0.71 | CYP1A2 (0.50) | — | |
| SCHEMBL31045211 | 0.70 | PRKCI (0.43) | — | |
| SCHEMBL3304818 | 0.70 | ADORA2A (0.64) | ADORA2AADORA1 | |
| SCHEMBL13389053 | 0.70 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL5432030 | 0.70 | ADORA2A (0.40) | ADORA2AADORA1 | |
| SCHEMBL31045111 | 0.69 | CYP1A2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2022236182-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | ADORA2A 2408/4885ADORA1 3648/4885TMIGD3 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.